BOSTON — eClinical Solutions LLC said argenx SE is expanding its use of the elluminate Clinical Data Cloud platform to improve clinical data oversight, streamline processes, and enhance operational efficiency across its trials.
The elluminate platform is designed to centralize and analyze clinical trial data from multiple sources, providing a unified system for communication and decision-making. Key components include tools for collaborative data review, self-service analytics and visualization, tracking of external data, and monitoring protocol deviations to support compliance and oversight.
The system also incorporates advanced capabilities such as elluminate eIQ Review, an AI-enabled data review and query automation tool, along with machine learning-driven audit trail review. The company said these features are intended to improve data quality and reduce cycle times in clinical development.
“We’re excited to continue supporting argenx’s commitment to future-proofing clinical trials with a modern data infrastructure,” said Raj Indupuri, CEO and co-founder of eClinical Solutions. “The expanded collaboration will aid argenx in innovating their data operations, enhance collaboration and data quality, and accelerate time to market in support of their vision to reach more patients with breakthrough science.”
The expanded adoption reflects growing demand for integrated, data-driven platforms as pharmaceutical and biotechnology companies seek to accelerate development timelines and improve the reliability of clinical trial outcomes.
